Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - fycompa
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpf8c80c0dde1cf12a2344c36d8be291f8
identifier: http://ema.europa.eu/identifier
/EU/1/12/776/001-023
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fycompa 2 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-f8c80c0dde1cf12a2344c36d8be291f8
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/12/776/001-023
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fycompa
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
Fycompa contains a medicine called perampanel. It belongs to a group of medicines called anti epileptics. These medicines are used to treat epilepsy - where someone has repeated fits (seizures). It has been given to you by your doctor to reduce the number of fits that you have.
Fycompa is used in association with other antiepileptic drugs to treat certain forms of epilepsy:
In adults, adolescents (aged 12 years and older), and children (from 4 to 11 years)
DO NOT TAKE Fycompa:
Warnings and precautions Talk to your doctor or pharmacist before taking Fycompa if you have liver problems or moderate or severe kidney problems. You should not take Fycompa if you have serious liver problems or moderate or serious kidney problems. Before taking this medicine you should tell your doctor if you have a history of alcoholism or drug dependence. Cases of increased liver enzymes have been reported in some patients taking Fycompa in combination with other antiepileptic drugs.
A small number of people being treated with anti-epileptics have had thoughts of harming or killing themselves. If at any time you have these thoughts, contact your doctor straight away.
Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens - Johnson Syndrome (SJS) have been reported with the use of perampanel.
Children Fycompa is not recommended for children aged under 4. The safety and effectiveness are not yet known in children under 4 years of age for partial seizures and under 7 years of age in generalised seizures.
Other medicines and Fycompa Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. Taking Fycompa with certain other medicines may cause side effects or affect how they work. Do not start or stop other medicines without talking to your doctor or pharmacist.
Fycompa with alcohol Speak to your doctor before drinking alcohol. Be careful about consuming alcohol with epilepsy medicines including Fycompa.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Do not stop treatment without first discussing it with your doctor.
Driving and using machines Do not drive or use machines until you know how Fycompa affects you. You must talk to your doctor about the effect of your epilepsy on driving and using machines.
Fycompa contains lactose Fycompa contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
How much to take
Adults, adolescents (aged 12 years and older) in treating partial seizures and generalised seizures:
The usual starting dose is 2 mg once a day before you go to bed.
The following table summarises the recommended doses in treating partial seizures in children 4 to 11 years of age and generalised seizures in children 7 to 11 years of age. More details are provided below the table.
Children weighing: More than 30 kg 20 kg to less than 30 kg Less than 20 kg Recommended starting dose 2 mg/day 1 mg/day 1 mg/day Recommended maintenance dose 4 8 mg/day 4 6 mg/day 2 4 mg/day Recommended maximum dose 12 mg/day 8 mg/day 6 mg/day
Children (from 4 to 11 years of age) weighing 30 kg or more in treating partial seizures:
The usual starting dose is 2 mg once a day before you go to bed.
Children (from 4 to 11 years of age) weighing 20 kg and less than 30 kg in treating partial seizures:
The usual starting dose is 1 mg once a day before you go to bed.
Children (from 4 to 11 years of age) weighing less than 20 kg in treating partial seizures:
The usual starting dose is 1 mg once a day before you go to bed.
Children (from 7 to 11 years of age) weighing 30 kg or more in treating generalised seizures:
The usual starting dose is 2 mg once a day before you go to bed.
Children (from 7 to 11 years of age) weighing 20 kg and less than 30 kg in treating generalised seizures:
The usual starting dose is 1 mg once a day before you go to bed.
Children (from 7 to 11 years of age) weighing less than 20 kg in treating generalised seizures:
The usual starting dose is 1 mg once a day before you go to bed.
How to take Swallow the tablet whole with a glass of water. You can take Fycompa with or without food. Do not chew, crush or split the tablet. The tablets cannot be split accurately as there is no break line.
If you take more Fycompa than you should If you have taken more Fycompa than you should contact your doctor straight away. You may experience confusion, agitation, aggressive behaviour and depressed level of consciousness.
If you forget to take Fycompa
If you stop taking Fycompa Take Fycompa for as long as your doctor recommends. Do not stop unless your doctor advises you to. Your doctor may reduce your dose slowly to avoid your fits (seizures) coming back or getting worse. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
A small number of people being treated with anti-epileptics have had thoughts of harming or killing themselves. If at any time you have these thoughts, contact your doctor straight away.
Very common (may affect more than 1 user in 10) are:
Common (may affect more than 1 user in 100) are:
Uncommon (may affect more than 1 user in 1000) are:
Not known (the frequency of this side effect cannot be estimated from the available data) are:
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of the month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Fycompa contains The active substance is perampanel. Each film-coated tablet contains 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, or 12 mg perampanel.
The other ingredients are: Tablet core (2 mg and 4 mg tablets): Lactose monohydrate, low-substituted hydroxypropyl cellulose, povidone, magnesium stearate (E470b)
Tablet core (6 mg, 8 mg, 10 mg and 12 mg tablets) Lactose monohydrate, low-substituted hydroxypropyl cellulose, povidone, microcrystalline cellulose, magnesium stearate (E470b)
Film coating (2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg tablets) Hypromellose 2910, talc, Macrogol 8000, titanium dioxide (E171), colourants*
*The colourants are: 2 mg tablet: Ferric Oxide, Yellow (E172), Ferric Oxide, Red (E172) 4 mg tablet: Ferric Oxide, Red (E172) 6 mg tablet: Ferric Oxide, Red (E172) 8 mg tablet: Ferric Oxide, Red (E172), Ferric Oxide, Black (E172) 10 mg tablet: Ferric Oxide, Yellow (E172), FD&C Blue #2 Indigo carmine aluminium lake (E132) 12 mg tablet: FD&C Blue #2 Indigo carmine aluminium lake (E132)
What Fycompa looks like and contents of the pack All strengths of Fycompa are round, biconvex film-coated tablets 2 mg: orange, marked with E275 on one side and 2 on other side 4 mg: red, marked with E277 on one side and 4 on other side 6 mg: pink, marked with E294 on one side and 6 on other side 8 mg: purple, marked with E295 on one side and 8 on other side 10 mg: green, marked with E296 on one side and 10 on other side 12 mg: blue, marked with E297 on one side and 12 on other side
Fycompa is available in packs of: 2 mg tablet pack of 7, 28 and 4 mg, 6 mg, 8 mg, 10 mg, 12 mg tablets packs of 7, 28, 84 and Not all pack sizes may be marketed
Marketing Authorisation Holder
Eisai GmbH Edmund-Rumpler-Stra e 3 60549 Frankfurt am Main Germany e-mail: medinfo_de@eisai.net
Manufacturer Eisai GmbH Edmund-Rumpler-Stra e 3 60549 Frankfurt am Main Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Eisai SA/NV T l/Tel: +32 (0)800 158 Lietuva Eisai GmbH Tel: + 49 (0) 69 66 58 (Vokietija)
Eisai GmbH Te .: + 49 (0) 69 66 58 ( )
Luxembourg/Luxemburg Eisai SA/NV T l/Tel: +32 (0)800 158 (Belgique/Belgien)
esk republika Eisai GesmbH organiza ni slo ka Tel: + 420 242 485 Magyarorsz g Ewopharma Hungary Kft.
Tel.: + 36 1 200 46 Danmark Eisai AB Tlf: + 46 (0) 8 501 01 (Sverige)
Malta Cherubino LTD Tel: +356 21343Deutschland Eisai GmbH Tel: + 49 (0) 69 66 58 Nederland Eisai B.V. Tel: + 31 (0) 900 575 3Eesti Eisai GmbH Tel: + 49 (0) 69 66 58 (Saksamaa)
Norge Eisai AB Tlf: + 46 (0) 8 501 01 (Sverige)
Arriani Pharmaceutical S.A. : + 30 210 668 3 sterreich Eisai GesmbH Tel: + 43 (0) 1 535 1980-0
Espa a Eisai Farmac utica, S.A. Tel: + (34) 91 455 94 Polska Eisai GmbH Tel: + 49 (0) 69 66 58 (Niemcy)
France Eisai SAS T l: + (33) 1 47 67 00 Portugal Eisai Farmac tica, Unipessoal Lda Tel: + 351 214 875 Hrvatska Eisai GmbH Tel: + 49 (0) 69 66 58 (Njema ka) Rom nia Eisai GmbH Tel: + 49 (0) 69 66 58 (Germania)
Ireland Eisai GmbH Tel: + 49 (0) 69 66 58 (Germany) Slovenija Eisai GmbH Tel: + 49 (0) 69 66 58 (Nem ija)
sland Eisai AB S mi: + 46 (0)8 501 01 (Sv j )
Slovensk republika Eisai GesmbH organiza ni slo ka Tel.: + 420 242 485 ( esk republika)
Italia Eisai S.r.l. Tel: + 39 02 5181Suomi/Finland Eisai AB Puh/Tel: + 46 (0) 8 501 01 (Ruotsi)
Arriani Pharmaceuticals S.A. : + 30 210 668 3( )
Sverige Eisai AB Tel: + 46 (0) 8 501 01 Latvija Eisai GmbH Tel: + 49 (0) 69 66 58 (V cija)
United Kingdom (Northern Ireland) Eisai GmbH Tel: + 49 (0) 69 66 58 (Germany)
This leaflet was last revised in {MM/YYYY}
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-f8c80c0dde1cf12a2344c36d8be291f8
Resource Composition:
Generated Narrative: Composition composition-en-f8c80c0dde1cf12a2344c36d8be291f8
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/12/776/001-023status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fycompa
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpf8c80c0dde1cf12a2344c36d8be291f8
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpf8c80c0dde1cf12a2344c36d8be291f8
identifier:
http://ema.europa.eu/identifier
/EU/1/12/776/001-023type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fycompa 2 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en